Roche to phase out microarray offering to focus on genome sequencing
This article was originally published in Scrip
Executive Summary
Roche is planning to close down or sell off its NimbleGen microarray business, according to media reports. Roche acquired NimbleGen for $272.5 million in 2007; if true, the rumours could mean it is abandoning the microarray market to focus on the faster-growing next-generation genome sequencing segment.